Tarsus Pharmaceuticals, Inc. [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Revenues:
Total revenues
Operating expenses:
Cost of license fees and collaboration revenue				0.5	0.0		0.1
Research and development	12.5	12.4	10.9	9.6	12.1	8.0	10.2	7.2
General and administrative	20.3	15.1	12.0	10.4	7.9	6.8	6.7	6.8
Total operating expenses	32.8	27.5	22.9	20.5	20.1		16.9
Loss from operations before other income (expense) and income taxes	-32.8	-25.0	-22.9	-5.2	-19.5	-14.4	-15.7	7.3

Other income (expense):
Interest income	2.2	2.3	1.1	0.3			0.0	0.0
Interest expense	-0.8	-0.7	-0.6	-0.5	-0.3
Other (expense) income, net	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
Unrealized gain (loss) on equity investments	0.0			-0.1
Change in fair value of equity warrants issued by licensee	0.0	0.0	0.0	-0.3	-0.2		-0.3	-0.9
Total other income (expense), net	1.4	1.5	0.4	-0.5	-0.7	-0.3	-0.3	-0.9
Provision for income taxes			0.0		0.0	0.1	0.3	0.0
Net (loss) income	-31.4	-23.4	-22.5	-5.7	-20.2	-14.9	-15.7	6.3

Other comprehensive loss:
Unrealized gain on marketable securities and cash equivalents	0.0	0.0
Comprehensive loss	-31.4	-23.4	-22.5	-5.7	-20.2	-14.9	-15.7	6.3

Earnings Per Share [Abstract]
Net loss per share, basic (usd per share)	($1.17)	($0.88)	($0.84)	($0.24)	($0.98)	($0.72)	($0.76)	$0.31
Net loss per share, diluted (usd per share)	($1.17)	($0.88)	($0.84)	($0.24)	($0.98)	($0.72)	($0.76)	$0.29

Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted-average shares outstanding, basic (shares)	26.8	26.7	26.7	24.3	20.7	20.6	20.6	20.6
Weighted-average shares outstanding, diluted (shares)	26.8	26.7	26.7	24.3	20.7	20.6	20.6	22.0